The cellular machinery regulating microRNA biogenesis and maturation relies on a small number of simple steps and minimal biological requirements and is broadly conserved in all eukaryotic cells. The same holds true in disease. This allows for a substantial degree of freedom in the engineering of transgenes capable of simultaneously expressing multiple microRNAs of choice, allowing a more comprehensive modulation of microRNA landscapes, the study of their functional interaction, and the possibility of using such synergism for gene therapy applications. We have previously engineered a transgenic cluster of functionally associated microRNAs to express a module of suppressed microRNAs in brain cancer for therapeutic purposes. Here, we provide a detailed protocol for the design, cloning, delivery, and utilization of such artificial microRNA clusters for gene therapy purposes. In comparison with other protocols, our strategy effectively decreases the requirements for molecular cloning, because the nucleic acid sequence encoding the combination of the desired microRNAs is designed and validated in silico and then directly synthesized as DNA that is ready for subcloning into appropriate delivery vectors, for both in vitro and in vivo use. Sequence design and engineering require 4-5 h. Synthesis of the resulting DNA sequence requires 4-6 h. This protocol is quick and flexible and does not require special laboratory equipment or techniques, or multiple cloning steps. It can be easily executed by any graduate student or technician with basic molecular biology knowledge.
Introduction
In the era of deep sequencing and comprehensive gene expression analysis, it has become evident that many diseases, ranging from neurodegenerationsystemic delivery of microRNA mimics in a phase 1 cancer clinical trial 15, 16 has discouraged the use of multiple microRNA combinations and has thus substantially limited their clinical impact. By contrast, vector-mediated delivery has the advantages of attaining expression levels nearer to physiological levels; can be regulated by tissue-specific promoters, thus maximizing the expression in specific tissues while sparing others; and generally allows for more prolonged expression. The limitations imposed by vectors' packaging capacity can be overcome by condensing multiple microRNAs within short DNA sequences, and thus the use of microRNA cluster structures is an attractive choice for maximizing the impact of microRNA modulation for both in vitro studies and in vivo applications. The polycistronic nature of certain microRNAs has been utilized for the overexpression of various arrays of inhibitory RNAs against HIV 17 , influenza 18 , cancer 19 , hepatitis 20 , and generic reporter genes 21 (Table 1) . In all cases, the purpose was to express synthetic inhibitory RNAs tailored to specific target genes, rather than recapitulating the physiological landscape and broad functions of natural microRNAs deregulated in diseases. In addition, those studies relied heavily on elaborate cloning techniques that are not immediately intuitive in regard to their technical execution and are possibly cumbersome for everyday applicability and adaptability to different gene therapy needs.
Applications of the method
We have used this protocol to demonstrate that the combinatorial modulation of three (ref. 13 ) to six ( Fig. 3c ) selectively chosen microRNAs normally expressed in healthy human brain has a synergistic anticancer effect by simultaneously targeting multiple oncogenic proteins, overcoming their ability to rescue each other's impaired function when targeted singularly 13 . We also show that these transgenes can be delivered in vivo by adeno-associated virus (AAV) vector injection into intracranial brain tumors, with marked survival benefit in a mouse preclinical model (Fig. 6c ). This protocol is easy to execute and takes advantage of the modular structure of microRNA genes. Accordingly, microRNA clusters can be dissected in silico into their functional components and rearranged into chimeric transgenes able to overexpress groups of multiple microRNAs. Because it is based on features that are common to all microRNAs, our method is generally applicable to any microRNA of interest, and is consequently very versatile. Moreover, the core of this protocol is based on the in silico design of the transgene, reducing the need for molecular cloning to a minimum. We believe that this protocol provides an easy method for the engineering of virtually any combination of microRNAs of choice into a transgene suitable for both in vitro and in vivo applications.
Limitations
Our protocol has the following limitations: 1 This protocol has been optimized for delivery to human cells, using the human miR- sequence as a scaffold. The microprocessor (i.e., the microRNA-processing complex, made by the proteins Drosha and DGCR8) is broadly conserved across animal and plant cells 22 , but it is possible that in other organisms a species-specific scaffold sequence might work more efficiently in the corresponding cells. 2 We have decided to utilize miR-17-92 as an ideal scaffold for our transgenic clusters, because, among the known microRNA clusters, it provides the highest number of microRNAs (six) within the shortest sequence of DNA (~1 kb). This is important for practical reasons, mainly the limitations imposed by the packaging capacity of delivery vectors. We expect that other microRNA clusters (e.g., the miR-302/367 cluster) will work in a similar manner. 3 Depending on the biological function of the microRNAs overexpressed by the transgene, it is possible that they might interfere with the basic biology of the cells used to produce virus particles (i.e., HEK293 cells), and this can result in lower vector titers when cytotoxic or tumor-suppressive microRNAs are used. 4 We have observed a progressive decrease in mature microRNA expression as the number of microRNAs encoded within the transgene increases. It is possible that as the transgene becomes larger, the cleavage efficacy of the microprocessor might decrease. Notwithstanding, even if the level of each given microRNA is comparatively decreased when they are processed from a six-hairpin structure as opposed to a single-or a three-hairpin structure, we found that the inhibitory effect of each microRNA on its respective target is not different and that the biological benefit of the microRNA summation is evident. 5 We have not tested transgenes encoding more than six hairpins. Although we hypothesize that a larger number of microRNAs can be successfully expressed, this might be limited by packaging size as well as microprocessor efficiency. 6 In vivo injection of viral particles can potentially cause toxicity, either because of the infection itself or because of off-target effects of the microRNAs in neighboring nontumor cells. We did not observe any toxicities in our experiments when using intracranial AAV injection in mice, and all animals tolerated the inoculation without any complications (i.e., seizures, neurologic deficits, weight loss, or premature death). However, the observed preferential tropism for human cells of the AAV vector used in this study ( Supplementary Fig. 1 ) might have masked potential toxicities.
Overview of the procedure
The key steps of this protocol are carried out in silico. First, the functional components of the miR-17-92 cluster (i.e., 5′ and 3′ flanking regions, microRNA hairpins, and spacing sequences, i.e., sequences separating each hairpin from the neighboring ones) are mapped. In the next step, the sequences encoding native microRNA hairpins are replaced with full, non-modified sequences encoding the microRNA hairpins of choice. Approximately 200 nt of both the 5′ and 3′ flanking regions of the chimeric microRNA in position 1 are used to replace the original miR-17-92 flanking regions. This (optional) step is performed to decrease the carryover of genetic elements belonging to an oncogene (miR-17-92) to the new transgene. Each flanking region is fitted with restriction sequences of choice for future subcloning. The native sequences separating the hairpins in the original miR-17-92 transgene are maintained to facilitate the correct RNA folding of the transcript. The resulting transgene is then verified for appropriate two-dimensional folding and maintenance of the hairpin structures by in silico analysis. Finally, the transgene is obtained by DNA synthesis and is subcloned into the desired delivery vector for downstream verification of microRNA expression and biological applications (Fig. 1) .
Experimental design
Choice of microRNA cluster This protocol is based on the genetic structure of the human miR-17-92 cluster, encoded in chromosome 13. This particular cluster was chosen because it has the highest number (six) of microRNA hairpins within the shortest DNA segment (~800 bp) among all other native microRNA cluster loci. This allows for a higher number of microRNA combinations.
Choice of substitute microRNAs
The selection of microRNA hairpins to replace native ones in the transgenic cluster is completely dependent on the goals of the investigator. All MicroRNA hairpins contain the intrinsic features necessary and sufficient to be accommodated within the transgene structure. We recapitulated the expression of several microRNAs expressed in normal brain (different combinations among miR-128, miR-124, miR-137, miR-7, miR-218, and miR-34a) but suppressed in glioblastoma, a brain cancer. We recommend using microRNAs that are already normally expressed in the healthy tissue (the brain in our case), in order to minimize off-target effects. Importantly, it is not necessary to reconstitute the full length of the cluster to maintain its functionality, and this protocol works well to overexpress any number of microRNAs between two and six.
Choice of appropriate control transgene For the negative control, we used a transgene constituted by using the same genetic scaffold as described above, but in which the 20-nt sequence encoding the leading microRNA strand of each hairpin was replaced with a scrambled sequence.
Choice of delivery vector
For in vitro applications, we have mainly used a third-generation lentiviral vector (pCDH-CMV-MCS-EF1-copGFP), in which the microRNA transgene is driven by a human cytomegalovirus (CMV) promoter. For in vivo gene delivery, we have used an AAV-serotype 2 vector with a CMV early enhancer-chicken β-actin promoter hybrid 23 to drive the transgene expression. In general, any vector can be used, as long as the packaging limit of the vector of choice is respected. The choice of the promoter driving the transgene expression should be made carefully, depending on the expected or known activity of that promoter in the cells of interest. We have observed very good expression levels with the human CMV promoter, but other RNA polymerase 2 promoters, such as EF1a or SV40, or cell-specific promoters are all compatible with the cassette.
Downstream studies
We have conducted the following types of downstream studies: 1 Verification of correct microRNA overexpression. After transgene delivery, transduced cells can be analyzed for the correct expression of each microRNA by quantitative RT-PCR or northern blot. We recommend waiting at least 48 h after transduction to allow sufficient time for microRNA processing. 2 Verification of appropriate microRNA function. The biological activity of each overexpressed microRNA is best assessed by western blot of the target proteins. Alternatively, a luciferase reporter assay-in which the 3′-UTR sequence of the reporter gene contains a specific recognition site for the microRNA(s) of interest-can be used. 3 Biological studies. Depending on the expected biological action of the microRNAs of interest, a wide array of functional studies can be performed. We have successfully tested cells for proliferation, apoptosis, clonal expansion, DNA repair, tumorigenicity in vivo and response to chemotherapy 13 .
Materials
Biological materials
• Human cell line HEK293 (ATCC, cat. no. CRL-1573, RRID: CVCL_0045) ! CAUTION The cell lines used in your research should be regularly checked to ensure that they are authentic and free of mycoplasma c CRITICAL HEK293 cells are fundamental to the production of high titers of both lentivirus and AAV vectors.
• Human primary glioma stem-like cells (GSCs) (GBM34 and GBM30 were a kind gift from E. A.
Chiocca's laboratory at Brigham and Women's Hospital) ! CAUTION The cell lines used in your research should be regularly checked to ensure that they are authentic and free of mycoplasma. We have authenticity checked regularly by IDEXX BioResearch. 
Reagents
• Transgene constructs. These were designed in silico by the authors and obtained though DNA synthesis from Invitrogen GeneArt Gene Synthesis services. The transgenes are received from the vendor as a DNA plasmid ready for subcloning into the desired vectors c CRITICAL Refer to the Supplementary Methods for a detailed list of reagents and procedures used for transgene cloning and viral vector packaging and preparation.
• Dulbecco's PBS (D-PBS; Gibco, cat. no. microRNA sequences for all species c CRITICAL For each hairpin, the program provides the specific nucleotides at which microprocessor cleavage occurs.
• Ensembl Genome Browser 95 (www.ensembl.org) This website provides access to the full genomic DNA sequence of the miR-17-92 cluster.
• RNAfold WebServer (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi) This program predicts the secondary structure of RNA sequences c CRITICAL This is important to verification of the maintenance of the hairpin structures in the transgenic sequences.
Software for the transgene sequence design • DNAStar Lasergene Sequence Builder tool (https://www.dnastar.com/manuals/installation-guide)
Alternatively, any text-editing software (i.e., Microsoft Word) can be used.
Reagent setup
Growth medium (for GSCs) Take 500 mL of neurobasal medium and add a 1/50 dilution (10 mL) of B-27 supplement. Add s 1/100 dilution (5 mL) of GlutaMAX from stock to obtain a final concentration of 2 mM. Then add 10 µL each of EGF (20 ng/mL) and FGF (20 ng/mL) from 100 µg/ml stocks. Add a 1/100 dilution (5 mL) of pen-strep stock. Invert the bottle a few times to ensure thorough mixing of all components. Store the bottle at 2-8°C in the refrigerator for no longer than 6 weeks.
Procedure Structural analysis of the miR-17-92 cluster and definition of its components • Timing: 2 h
c CRITICAL The precise recognition of microRNA hairpins and their cleavage sites by the microprocessor is the fundamental step of this protocol. Maintenance of the 2D structural integrity of the hairpins is essential for their correct processing. 1 Retrieve the genomic sequence of the human miR-17-92 cluster and export it to Sequence Builder or Microsoft Word for editing. Access the sequence at http://useast.ensembl.org/Homo_sapiens/Loca tion/View?db=core;g=ENSG00000215417;r=13:91350433-91351620;mr=13:91350445-91351602. 2 Click on 'export data'. Use default page settings. Confirm that the genomic location is chromosome 13, position 91350433 to 91351620. Click 'next' and select 'Text' as the output format. This opens a .txt file containing the FASTA sequence of the specified genomic region. c CRITICAL STEP The presence of RNA regions flanking the hairpin is fundamental to correct microRNA processing 24 . Select 200 nt in the 5′ region upstream of the microRNA hairpin in position 1 and 200 nt in the 3′ region downstream of microRNA hairpin 6. In our experience, microRNA processing of even a single hairpin is substantially decreased when the flanking regions are <100-150 nt. 3 Obtain the sequence of each of the six microRNA hairpins encoded in the cluster from miRBase.
Take note of the exact nucleotides at the site of microprocessor cleavage (this is color-coded in the website graphical output) (Fig. 2a,c) . 4 Map the six sequences obtained in Step 3 against the full cluster sequence from Step 1 to obtain the precise location of each microRNA hairpin, as well as any spacer sequences, and the boundaries with flanking regions within the locus (Figs. 1b,2b ). c CRITICAL STEP It is fundamental to exactly mark the microprocessor cleavage sites for each hairpin, because this is critical to the downstream design of the transgene and to its correct processing.
Replacement of native miR-17-92 hairpins with the desired substitute hairpins • Timing: 1 h 5 Obtain the sequences of the microRNAs of interest from miRBase. As described above, make note of the microprocessor cleavage sites (Fig. 2c ). 6 Starting from hairpin 1 (the hairpin in the most 5′ position), delete the sequence encoding each native hairpin, except for the first 3-5 nt at the 5′ and 3′ ends of the hairpin, which should still retain a base-pairing configuration (Fig. 2c) . We determine the length of this acceptor sequence (i.e., 3 versus 4 versus 5 nt) on the basis of the requirement to have three Watson-Crick base pairs (A-T or C-G) within that sequence. c CRITICAL STEP This 3-to 5-nt sequence allows the two regions flanking the microRNA to initiate a stem structure and function as an acceptor for the new chimeric microRNA hairpin (Fig. 2a,c,d ). 7 Replace the deleted hairpin sequence with that of the desired microRNA. c CRITICAL STEP Make sure to include at least 8 bp from the replacing hairpin, proximal to the microprocessor cleavage site, to allow for the formation of a stem of appropriate length (>11 bp), which is an essential requirement for correct microRNA processing 25 (Fig. 2d) . ? TROUBLESHOOTING 8 Repeat Steps 6 and 7 for the desired number of microRNAs, up to a total of six. In particular, the length of the stem proximal to the site of the microprocessor cut has been maintained at ≥11 nt, by leaving 3 nt from the original miR-17 stem sequence. The spacer sequence is also identical. The 3 nt at the base of the stem (red dashed circle) are also maintained.
11 Add 5 nt of choice (the sequence is not important) at each end of the sequence to allow enough space for DNA cleavage by the restriction enzymes.
In silico validation of the transgene structure • Timing 15 min 12 Paste the resulting sequence into the RNA secondary structure prediction software (RNAfold WebServer) and proceed with the standard, preset configuration. 13 Analyze the graphic output by clicking the 'FORNA' option. c CRITICAL STEP Verify that each microRNA hairpin is properly structured and that there are at least 11 nt of highly complementary stem proximal to the microprocessor cleavage site, without any branching points (Fig. 3) . In our experience, satisfaction of this requirement is an important predictor of successful microRNA processing. c CRITICAL STEP Changing the flanking regions does not affect microRNA processing (Fig. 4) . ? TROUBLESHOOTING DNA synthesis • Timing 4-6 h 14 Submit the validated transgene sequence for DNA synthesis. This can be done in-house for laboratories that have such capability. We have consistently had excellent results by outsourcing the synthesis of DNA to a vendor. j PAUSE POINT After synthesis, the DNA can be stored at −20°C indefinitely.
Transgene cloning and preparation of viral vectors • Timing 3 d
15 To clone transgenes and prepare viral vectors, follow the manufacturers' standard instructions for DNA ligation, bacterial transformation, clone screening by restriction digestion, and packaging of viral vectors, as provided in the Supplementary Methods.
Transgene delivery in vitro • Timing 1 h
c CRITICAL Before performing any downstream applications with the microRNA clusters, it is critical to evaluate the proper processing of the transgenes by measuring the level of mature microRNAs produced after their transduction into the cells of interest (Fig. 3) . 16 Incubate the G34 primary GSCs with Accutase for 5 min at 37°C until they are dissociated to single cells. 17 After counting, place 150,000 cells in a 15-mL conical tube, bring the volume to 5 mL with ice-cold PBS, and centrifuge at 300g for 5 min at 4°C. 18 Remove the supernatant with a Pasteur pipette, leaving a small pellet of cells undisturbed. 19 Pipette 50 μl of the concentrated lentivirus (totaling 5 × 10 7 viral particles) containing microRNA transgenes from Step 15 on top of the cell pellet. Gently flick the tube three to five times to mix the cells with the virus within the small~50-μl volume. c CRITICAL STEP We have observed that performing the infection in a small volume within a 15-mL centrifuge tube allows for greater transduction as compared with inoculation of the same amount of virus when cells are dispersed in culture. ? TROUBLESHOOTING 20 Incubate at 37°C for 30 min with occasional flicking of the tube. 21 Resuspend the cells in 5 mL of pre-warmed culture medium and transfer them to culture flasks in a cell incubator set to 37°C. 22 Successfully transduced cells usually begin to express GFP 48 h after infection. At that point, wash the cells once with 10 mL of ice-cold PBS, pellet them by centrifugation at 300g for 5 min at 4°C to remove any leftover virus particles, resuspend the pellet in fresh medium, and place the cells back into the incubator at 37°C to further expand the culture for an additional 5 d.
Analysis of transgene expression • Timing 3 h
23 One week after infection, select cells stably expressing the microRNA transgene by GFP-mediated FACS 26 and expand them in culture. Sorted cells can be cultured for at least 1 month (five to six passages) without measurable decline in the expression of either GFP or microRNAs. ? TROUBLESHOOTING 24 One week after sorting, collect cells and extract the total RNA by using TRIzol or another available RNA extraction kit compatible with microRNA isolation and following the manufacturer's instructions. . Each hairpin is color-coded and labeled on the structure. Red arrowheads represent the cleavage points by a microprocessor. b, Relative quantification (RQ) of microRNA expression by RT-qPCR of G34 GBM cells infected with lentivirus expressing either negative control or cluster 3 transgene. Image adapted from Bhaskaran et al. 13 under a Creative Commons Attribution 4.0 license (https://creativecommons.org/licenses/by/4.0/legalcode). c, Graphical output of a transgene expressing the chimeric microRNA hairpins of miR-128, miR-124, miR-137, miR-7, miR-218, and miR-34a (cluster 6). Each hairpin is color-coded and marked on the structure. Red arrowheads represent the cleavage points by a microprocessor. d, RQ of microRNA expression by RT-PCR of G34 GBM cells infected with lentivirus expressing either negative control or cluster 6 transgene. e, Predicted structure of a transgene derived from cluster 3, containing a 20-nt scrambled sequence replacing each microRNA of the transgene (scrambled cluster 3). Note the absence of hairpin formation, the presence of branching points, and the absence of microRNA expression. f, RQ of microRNA expression by RT-PCR of G34 GBM cells infected with lentivirus expressing either negative control or scrambled cluster 3 transgene. For all experiments, the means ± s.d. of n = 3 independent experiments are reported. *P < 0.05; **P < 0.01; ***P < 0.001 (two-tailed Student's t-test). CL3, cluster 3; CL6, cluster 6; Ctrl, control; lenti, lentivirus. Step 15 in 5 µL of PBS into a Hamilton syringe and assemble it into the stereotactic apparatus. c CRITICAL STEP Because of the small volume allowed for intracranial injection, it is essential that the virus titer be >1 × 10 9 to allow for substantial infection. c CRITICAL STEP Although lentivectors have provided a very reliable method for transducing cells in cultures, in our experience, they have not shown good infectivity when delivered intracranially. In our experience with brain tumor cells, adeno-associated virus serotype 2 is substantially more efficient for in vivo use, and thus it was used in that setting. 31 Introduce the needle intracranially, following the exact stereotactic coordinates used for inoculating the tumor cells. 32 Inject the virus solution at a rate of 1 μL/min. 33 Leave the needle in place for 5 min to decrease the virus reflux along the needle tract. 34 At the end of the surgery, place the mouse in a warm cage until it completely recovers from anesthesia. After recovery, a subcutaneous dosage of buprenorphine (0.05 mg/kg) is administered to each mouse. The same dosage was given one more time after a 12-hour period. ? TROUBLESHOOTING The data show that sequence changes in the 5′ flanking region of the transgene do not affect microRNA processing, whereas changes in the sequences separating the microRNA hairpins (spacers) decrease the processing efficiency. The means ± s.d. of n = 3 independent experiments are reported. *P < 0.05; **P < 0.01; ***P < 0.001 (two-tailed Student's t-test); NS, nonsignificant.
Analysis of transgene expression ex vivo • Timing 4 h
35 Euthanize the animal at the desired time point for evaluation of transgene expression in target cells. ! CAUTION Make sure that the use of animals is performed according to protocols previously reviewed and approved by the relevant IACUC. c CRITICAL STEP We recommend waiting for at least 3 d after infection, to allow for full virus transduction and transgene expression, but it is best to perform the analysis within the first 7 d (Supplementary Fig. 2) . 36 Perfuse the brain with PBS through a transcardiac infusion of 10 mL of ice-cold PBS to remove the blood. 37 Remove the brain from the skull and isolate the hemisphere that had been previously inoculated with the tumor and the virus particles. 38 Using a benchtop magnifying lens, grossly isolate the tumor tissue from the normal brain and place it in ice-cold PBS. 39 Incubate the tissue with Accutase for 1 h at 37°C; then dissociate to single cells by passing the tissue through a fire-polished Pasteur pipette and filtering it through a 40-µm cell strainer. 40 Extract the RNA and perform PCR as described in Steps 25 and 26.
Troubleshooting
Because of the modular nature of microRNA hairpins, we have consistently observed that satisfactory in silico analysis of the transgene structure was 100% predictive of successful transgene processing. It is, however, possible that in some instances the folding and processing of certain microRNAs might not be as anticipated. In such cases, we suggest moving the sequence encoding the specific microRNA hairpin to a different position within the transgene, because this might produce a more favorable folding of the primary sequence. Another option, more tailored to microRNAs with a short stem, is to lengthen the stem acceptor sequence by adding several more complementary base pairs (in addition to the three used as default in the standard protocol). This will facilitate the formation of the hairpin and its cleavage.
We encourage the use of vectors that simultaneously express a reporter gene (RFP, GFP, or the antibiotic resistance gene) to confirm appropriate cell transduction in the case of low or absent microRNA expression. In cases in which the reporter gene is present, but no microRNAs are detected, it is important to rule out whether the problem occurred at the microRNA processing or at the transcription level. PCR of the primary transcript should be performed to exclude the latter. This can be done by designing sequence-specific primers encompassing the 5′ flanking region of the cluster (forward primer) and the first microRNA hairpin (reverse primer), after removing any genomic DNA carryover by DNase digestion (Supplementary Fig. 3 ). In cases of low transduction efficiency, increase the amount of viral particles per infection, being careful to monitor for cell toxicity.
Further troubleshooting advice can be found in Table 2 . 
Anticipated results
The design of transgenic microRNA clusters described in this protocol allows for reliable and predictable overexpression of multiple microRNAs while retaining their natural capacity to downregulate the translation of their mRNA targets. We have used this strategy to simultaneously reestablish the expression of three neuronal microRNAs (miR-124, miR-128, and miR-137) in GBM cells, resulting in the inhibition of multiple key oncogenes and substantial antitumor effects 13 . Adherence to this protocol routinely yields RNA sequences with favorable structural conformations that are effectively processed into mature microRNAs (Fig. 3) . Depending on the basal expression level of each microRNA in target cells, a 10-to 250-fold increase in expression is generally achieved by the transgene. We have also demonstrated the flexibility of our protocol by expanding the pool of chimeric microRNAs from three to six, all of which displayed robust expression in GBM cells. Data regarding a three-microRNA cluster have already been published 13 . Data on the six-microRNA transgene have not been previously published, but this approach has confirmed the biological relevance of reconstituting the expression of progressively larger clusters of microRNAs (Fig. 5 , also see Supplementary Methods for detailed descriptions of the western blot protocol and analysis of cell proliferation). Interestingly, when multiple microRNAs share the same target, their combination does not appear to be synergistic or additive against that specific mRNA. For example, SP1 and JAG1 are independently targeted by miR-124, miR-128, and miR-137. Yet the level of inhibition of these two oncogenes does not substantially increase when the three microRNAs are overexpressed together, suggesting that microRNA clustering works preferentially by expanding the targetome rather than strengthening the inhibition of shared targets ( Supplementary Fig. 4 ). Importantly, we have shown the versatility of our transgenic construct by cloning the three-microRNA transgene (cluster 3) into AAV vectors. In vivo, intratumoral inoculation of these AAV vectors resulted in tumor cell transduction, expression of transgenic microRNAs, and marked antitumor effect in a mouse GBM model (Fig. 6 , also see Supplementary Methods for a detailed description of ex vivo tissue processing and microscopy). We expect that any vectors commonly used in gene delivery will support the expression of the transgenic cassette, for both in vitro and in vivo use. Determination of the best vectors depends on the characteristics of each biological context (e.g., in vitro versus in vivo, tumor cells versus nontumor cells, localized versus systemic targeting) and is beyond the scope of this protocol. The Figs. 1 and 2 ) is expected to support the overexpression of any desired microRNA combinations for at least six microRNAs.
Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article. BMI1 is a specific target of miR-128; EZH2 and LSD1 are specific targets of miR-124 and miR-137, respectively. BCL2 is a specific target of miR-34a. H3 was used as loading control. Detailed descriptions of the western blot and cell proliferation analysis procedure are provided in Supplementary Methods. ***P < 0.001; ****P < 0.0001 (two-tailed Student's t-test). CL3, cluster 3; CL6, cluster 6; Ctrl, control; H3, histone 3; lenti, lentivirus. (data not shown) . The means ± s.d. from n = 3 mice per group are reported. *P < 0.05; **P < 0.01 (two-tailed Student's t-test). c, Kaplan-Meier survival curve 27 of the mice from a (data not shown). The timing of intracranial tumor implantation and intratumoral virus injection is marked along the x axis. n = 6 mice per group. Eight mice per group (control vs. cluster 3 groups) were inoculated with AAVs. Two mice per group were killed for histology examination and were not counted toward the analysis of survival. All animals tolerated the procedure well and none died unexpectedly or showed signs of distress or toxicity. All deaths were due to tumor progression. All animal experiments were done in compliance with all relevant ethical regulations applied to the use of small rodents and with approval of the institutional animal care and use committees (IACUCs) at Brigham and Women's Hospital and Harvard Medical School.
Data availability
The data that support the findings of this study but are not directly available within the paper and its Supplementary Methods files are available from the corresponding author upon reasonable request. This includes DNA sequences of all transgenes used in this study. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Software and code
Policy information about availability of computer code Data collection microRNA sequence information were obtained from publicly available miRBase and ensembl data base. RNAfold Web Server was used to determine the secondary structure of the RNA sequences.
Data analysis
Sequence designing was done using Sequence Builder tool (LaserGene) and Microsoft Word. All other analysis were performed using GraphPad Prism, Version 6.0
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Sample size
All survival animal studies were performed with at least 6 animals per group Data exclusions No data were excluded from analysis
Replication
All experiments were replicated three times, unless otherwise specified in figure legends.
Randomization Randomization was performed for the in vivo AAV injection, whereby animals were initially injected with the same amount of GBM cells and then, at time of AAV injections, they were divided randomly into two equal groups of 6 animals, receiving control or microRNA AAVs, respectively.
Blinding
Blinding was not possible in this study as the authors needed to be aware at any given time of the transgene or treatment applied to each sample.
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Validation
Each and every antibody used in this manuscript was tested and validated by the respective vendor for the specific application for which it was used in our experiments.
Eukaryotic cell lines Policy information about cell lines
Cell line source(s) G34 and G30 glioblastoma stem-like cells were previously isolated from primary glioblastoma specimens in our laboratory. HEK293 cell lines were previously purchased from ATCC and stored in our laboratory cell repository.
Authentication
G34 and G30 cells were analyzed and autenthicated as human by Idexx Bioresearch (www.idexbioresearch.com) using short tandem repeat profiling.
Mycoplasma contamination
G34 and G30 cells were tested for mycoplasma and resulted negative for contamination (analysis performed by Idexx Bioresearch)
Commonly misidentified lines (See ICLAC register) none
